LLNL and Penn State researchers developed a new approach to study and purify medical isotopes, including actinium. (Image: Thomas Reason/LLNL)
Scientists at Lawrence Livermore National Laboratory and Pennsylvania State University have demonstrated that a natural protein found bonded to rare earth elements can be recovered and used as a tool to purify and effectively manage radioactive metals that show promise for cancer therapy and the detection of illicit nuclear activities.
Physicist Suying Jin with computer-generated images showing the properties of heat pulse propagation in plasma (Image: PPPL/Jin/Kiran Sudarsanan)
Researchers at the Department of Energy’s Princeton Plasma Physics Laboratory (PPPL) have developed a new model of how heat flows within plasmas. According to PPPL, the model could improve insights into the behavior of plasmas and may help engineers avoid the conditions that could lead to heat loss in future fusion facilities.
Five sites have been shortlisted for the U.K.’s STEP fusion facility. (Image: UKAEA)
The United Kingdom has announced a shortlist of five sites as the potential future home of the U.K. Atomic Energy Authority’s (UKAEA) prototype fusion energy plant, the Spherical Tokamak for Energy Production (STEP). A final decision on the plant’s location is to be made by the U.K.’s secretary of state for business, energy and industrial strategy around the end of 2022.
This June 2021 photo of ITER vacuum vessel sector #6 includes two panels of thermal shielding ready to slide into place. (Photo: ITER/Courtesy of Chang Hyun Noh)
Following a week of heightened attention to all things hydrogen preceding Hydrogen and Fuel Cell Day (October 8), Bernard Bigot, director general of the ITER Organization, published an op-ed on October 11 in The European Files, a magazine billed as an “effective work tool for European deciders.” Bigot’s article, “Hydrogen fusion: The way to a new energy future,” doubled as a fusion primer, promoting the technology as a future source of clean energy that is fueled by hydrogen and is capable of providing heat and power to produce more hydrogen.
Balázs Bodnár, managing director of Framatome Hungary (left), shakes hands with Habil István András, rector of the University of Dunaújváros, joined by Ferenc Berki, president and CEO of Hunatom. (Photo: Framatome)
The Hungarian office of Framatome this week signed a memorandum of understanding with Budapest-based research and economic development company Hunatom and the University of Dunaújváros to work together supporting nuclear education and training, research and development, and implementation of new technologies for Hungary and surrounding countries.
Representatives of the three organizations signed the MOU during a ceremony at Hungary’s University of Dunaújváros, about 40 miles south of Budapest.
(University of Rochester illustration/Michael Osadciw)
The U.K. government has just published Towards Fusion Energy: The UK Government’s Fusion Strategy, which sets out the goal of the United Kingdom's moving from “a fusion science superpower to a fusion industry superpower,” with a prototype fusion power plant being built in the country by 2040.
While a slightly ambitious plan, there are now about 20 startup companies working to achieve a Wright brothers’ moment in fusion sooner than that. This includes Commonwealth Fusion Systems, which is aiming for a working fusion power plant by 2030 and is the subject of Rivka Galchen’s October 4 New Yorker article, “Can Nuclear Fusion Put the Brakes on Climate Change?”
Illustration of a normal human heart showing ventricles and valves. (Image: Patrick J. Lynch, medical illustrator; C. Carl Jaffe, M.D., cardiologist)
Therapeutic radiation is typically reserved for cancer treatment, but scientists at Washington University School of Medicine in St. Louis have applied radiation therapy to treat ventricular tachycardia, a life-threatening heart arrhythmia. A news release issued by the university says that the results of the study show that radiation therapy can “reprogram” heart muscle cells to “a younger and perhaps healthier state.” The findings were published in the journal Nature Communications on September 24.
A conceptual image of collaboration across Europe. (Image: PRISMAP/SCIPROM)
Only a few of the more than 3,000 radioisotopes that scientists have synthesized in the laboratory are regularly used in diagnostic or therapeutic medicine. One significant barrier to the development of new medical radioisotopes is the difficulty of gaining access to radionuclides during the early stages of development and research. PRISMAP is a new medical radionuclide program designed to streamline that access for medical research in the European Union and the United Kingdom.
Explore Kairos Power’s plans in a virtual open house.
By 2030, Kairos Power aims to demonstrate electricity production from a full-scale, 140-MWe fluoride salt–cooled high-temperature reactor, the KP-X. In service of that goal, Kairos plans to demonstrate Hermes, a scaled-down 35-MWth nonpower reactor, in Oak Ridge, Tenn.
Hermes is being built to “prove our ability to deliver affordable nuclear heat,” said Mike Laufer, Kairos Power chief executive officer and cofounder, as he explained Kairos’s plans to the local community during a September 28 webinar now available to view on demand. Laufer took questions, and Kairos took the opportunity to introduce a virtual open house that visitors can tour to view videos and interactive features and even submit comments.
The Bruce nuclear power plant in Ontario, Canada. (Photo: Bruce Power)
Bruce Power has received approval from the Canadian Nuclear Safety Commission (CNSC) to begin the production of lutetium-177, becoming the first power reactor globally to commercially produce the medical radioisotope. Isogen, a joint venture between Framatome and Kinectrics, will produce Lu-177 at Bruce’s eight-unit CANDU nuclear power plant in Ontario, Canada, using Isogen’s isotope production system (IPS).
The core of SLOWPOKE-2. (Photo: CNL)
Canadian Nuclear Laboratories (CNL) announced on September 23 that it had refueled the SLOWPOKE-2 research reactor at the Royal Military College of Canada (RMC) in Kingston, Ontario. The reactor was recommissioned on September 10 after a 22-day outage.
Don Perrie (left), of OPG, and Michael Lefebvre, of Laurentis Energy Partners, examine the He-3 extraction tool installed at Darlington NPP
Laurentis Energy Partners, a subsidiary of Ontario Power Generation (OPG), has launched a new program to produce helium-3. The He-3 will be obtained from tritium stored at OPG’s Darlington nuclear power plant, a four-unit CANDU station located about 100 kilometers east of Toronto.
Darlington houses one of the world’s largest reserves of tritium, which is a by-product of the heavy water used in CANDU reactors.
This large-bore, full-scale high-temperature superconducting magnet designed and built by Commonwealth Fusion Systems and MIT’s Plasma Science and Fusion Center is the strongest fusion magnet in the world. (Photo: Gretchen Ertl, CFS/MIT-PSFC)
A high-temperature superconducting magnet reached and maintained a magnetic field of more than 20 tesla in steady state for about five hours on September 5 at MIT’s Plasma Science and Fusion Center. Not only is the magnet the strongest high-temperature superconducting (HTS) magnet in the world by far, it is also large enough—when assembled in a ring of 17 identical magnets and surrounding structures—to contain a plasma that MIT and Commonwealth Fusion Systems (CFS) hope will produce net energy in a compact tokamak device called SPARC in 2025, on track for commercial fusion energy in the early 2030s.